| 廖佳,李翠霞.缬沙坦联合卡托普利对慢性肾小球肾炎患者血液流变学的影响[J].中国药事,2018,32(4):562-566 |
| 缬沙坦联合卡托普利对慢性肾小球肾炎患者血液流变学的影响 |
| Effect of Valsartan Combined with Captopril on Hemorheology in Patients with Chronic Glomerulonephritis |
| 投稿时间：2017-07-11 |
| DOI：10.16153/j.1002-7777.2018.04.023 |
| 中文关键词: 缬沙坦 卡托普利 肾炎 血液流变学 临床疗效 |
| 英文关键词: valsartan captopril nephritis hemorheology clinical effect |
| 基金项目: |
|
| 摘要点击次数: 1201 |
| 全文下载次数: 842 |
| 中文摘要: |
| 目的：探讨缬沙坦联合卡托普利对慢性肾小球肾炎（CGN）患者血液流变学的影响。方法：选取2013年12月至2016年12月黄石人福医院确诊治疗的CGN患者150例，依据随机分配原则分为单沙坦组、单普利组、普利沙坦组，每组50例，单沙坦组给予80 mg缬沙坦口服治疗，每天1次，共4周，单普利组给予25 mg卡托普利口服治疗，每天2次，共4周，普利沙坦组给予缬沙坦联合卡托普利治疗。结果：普利沙坦组治疗2、4周后，24 h尿蛋白定量（24hUP）水平和治疗结束后血浆黏度（ηb）、红细胞比容（HCT）、血小板聚集率（PAR）水平明显低于单沙坦组、单普利组，普利沙坦组治疗有效率明显高于单沙坦组、单普利组，差异有统计学意义（P<0.05），单沙坦组、单普利组上述指标水平基本相同，差异无统计学意义（P > 0.05）；单沙坦组、单普利组、普利沙坦组不良反应发生率基本相同，差异无统计学意义（P > 0.05）。结论：缬沙坦联合卡托普利治疗可有效改善CGN患者血液流变学水平，有利于保护患者肾功能及提高治疗效果，且具有良好的安全性。 |
| 英文摘要: |
| Objective: To discuss the effect of valsartan combined with captopril on hemorheology in patients with chronic glomerulonephritis (CGN). Methods: 150 patients with CGN diagnosed and treated in this hospital from December 2013 to December 2016 were selected. The patients were randomly divided into valsartanonly group, captopril-only group, captopril combined with valsartan group according to the principle of random distribution, with 50 cases in each group. The valsartan-only group was orally given 80 mg of valsartan, qd for four weeks. The captopril-only group was orally given 25 mg of captopril, bid for four weeks. The captopril combined with valsartan group was given valsartan and captopril. Results: Levels of urine protein quantitative (24hUP) 2 and 4 weeks after treatment, levels of plasma viscosity(ηb), hematocrit value (HCT), platelet aggregation rate (PAR) after treatment in the captopril combined with valsartan group were signifcantly lower than those of valsartan-only group and captopril-only group. The therapeutic response rate of captopril combined with valsartan group was signifcantly higher than those of valsartan-only group and captopril-only group. There was no statistically signifcant difference (P<0.05) of the above mentioned levels of the parameters of valsartanonly group and captopril-only group. The incidences of adverse reaction of valsartan-only group, captoprilonly group and captopril combined with valsartan group were basically the same, without statistically signifcant difference (P > 0.05). Conclusion: Valsartan combined with captopril treatment can effectively improve the hemorheology of patients with CGN, protect the renal function of patients, improve the therapeutic effect and it is quite safe. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |